← SynDRA

ERTUGLIFLOZIN

SynDRA canonical compound SYN0026866 — structure-anchored drug synonym record

All known targets

• SLC5A2
• SLC5A1
• SLC5A4
• Slc5a2

Mechanisms of action (all sources)

• SLC5A2 INHIBITOR
• Sodium/glucose cotransporter 2 inhibitor
• sodium/glucose cotransporter inhibitor
• SLC5A2 MODULATOR

Drug classes

• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors

ATC classes

• A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

Cross-references

• PubChem CID: 44814423
• ChEMBL: CHEMBL1770248
• DrugBank: DB11827
• ChEBI: 188719
• KEGG: D10313
• RxNorm: 1992672
• Wikipedia: Ertugliflozin
• TTD: D0Q3VE

Synonyms

• PF-04971729-00
• steglatro
• ertugliflozin L-pyroglutamic acid
• PF-04971729
• ERTUGLIFLOZINE
• ERTUGLIFLOZINA
• CHEMBL1770248
• MK-8835
• PF04971729
• PF 04971729
• UNII-6C282481IP
• 6C282481IP
• AK174928
• 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
• Steglatro
• (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol
• (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol
• Ertugliflozin [USAN:INN]
• C22H25ClO7
• PF-4971729
• SGLT2 inhibitor (oral, type 2 diabetes), Pfizer
• Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer
• Ertugliflozin/PF-04971729
• PF 04971729-00
• ertugliflozina
• ertugliflozine
• ertugliflozinum
• RefChem:56924
• DTXCID4075611
• A10BK04
• MFCD21609259
• Ertugliflozin (PF 04971729)
• Ertugliflozin (Standard)
• ERTUGLIFLOZIN [MI]
• ERTUGLIFLOZIN [INN]
• Ertugliflozin (USAN/INN)
• ERTUGLIFLOZIN [USAN]
• SCHEMBL181047

Reported adverse events

• Thirst
• Urinary tract infection
• Back pain
• Headache
• Ketoacidosis
• Nasopharyngitis
• Phimosis
• Pyelonephritis
• Weight
• Weight decreased
• Urosepsis
• Arthralgia